AbCellera Biologics (ABCL) Asset Utilization Ratio (2021 - 2026)

AbCellera Biologics has reported Asset Utilization Ratio for 6 years, with the latest figure at 0.06 in Q1 2026.

• For the quarter ending Q1 2026, Asset Utilization Ratio rose 247.9% year-over-year to 0.06; the trailing twelve-month figure through Mar 2026 stood at 0.06 (up 247.9% YoY), and the FY2025 full-year result was 0.06, up 173.14% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.06, up from 0.06 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 0.38 in Q3 2022, with the low at 0.02 in Q1 2025.
• Historically, Asset Utilization Ratio has averaged 0.11 across 5 years, with a median of 0.03 in 2023.
• Annual changes were most pronounced in 2023 — Asset Utilization Ratio sank 91.92% — and 2026, when it surged 247.9%.
• AbCellera Biologics' Asset Utilization Ratio stood at 0.31 in 2022, then slumped by 91.92% to 0.03 in 2023, then decreased by 17.37% to 0.02 in 2024, then surged by 164.43% to 0.06 in 2025, then advanced by 7.37% to 0.06 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.06 (Q1 2026), 0.06 (Q4 2025), and 0.03 (Q3 2025), per Business Quant data.